Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

Achim Rothe, MD, Stephanie Sasse, MD, Max S. Topp, MD, Dennis A. Eichenauer, MD, Bastian von Tresckow, MD, Horst-Dieter Hummel, MD, Miroslav Ravic, MD PhD, Jens-Peter Marschner, MD, Andreas Engert, MD

Blood (2014) 124 (21): 1753.

https://doi.org/10.1182/blood.V124.21.1753.1753

Published: 2014

Journal Articles

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Eugene Zhukovsky, PhD, Achim Rothe, MD, Bastian von Tresckow, MD, Max Topp, Anas Younes, MD, Dennis A. Eichenauer, MD, Horst Hummel, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Joerg Kessler, PhD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Poggevon Strandmann, PhD, Andreas Engert, MD

Blood (2013) 122 (21): 5116.

https://doi.org/10.1182/blood.V122.21.5116.5116

Published: 2013

Journal Articles

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Bastian von Tresckow, MD, Helen Görgen, Annette Plütschow, PhD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Achim Rothe, MD, Michael Fuchs, MD, Karolin Behringer, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2013) 122 (21): 4231.

https://doi.org/10.1182/blood.V122.21.4231.4231

Published: 2013

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Achim Rothe, MD, Stephanie Sasse, MD, Helen Goergen, Dennis A. Eichenauer, MD, Andreas Lohri, MD, Ulrich Jäger, Christopher Bangard, Andreas Engert, MD

Blood (2012) 120 (21): 2743.

https://doi.org/10.1182/blood.V120.21.2743.2743

Published: 2012

Journal Articles

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Achim Rothe, MD, Anas Younes, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Dennis A. Eichenauer, MD, Joerg Kessler, Max S. Topp, MD, Horst Hummel, MD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Pogge von Strandmann, PhD, Andreas Engert, MD

Blood (2011) 118 (21): 3709.

https://doi.org/10.1182/blood.V118.21.3709.3709

Published: 2011

Journal Articles

A Bispecific Protein Targeting the NKG2D Receptor on Natural Killer Cells: In Vitro and In Vivo activity of ULBP2-CEA

Marie Madlener, Achim Rothe, MD, Ron Jachimowicz, Katrin S. Reiners, PhD, Sampurna Chatterjee, Roland Ullrich, MD, Paul Yazaki, PhD, Andreas Engert, MD, Elke Pogge von Strandmann, PhD

Blood (2010) 116 (21): 2095.

https://doi.org/10.1182/blood.V116.21.2095.2095

Published: 2010

Journal Articles

Selection of Human Anti-CD22 scFvs from an Acute Lymphocytic Leukemia Related scFv Library with Ribosome Display.

Achim Rothe, MD, Ralf J. Hosse, PHD, Anne Nathanielsz, RA, Frank Oberhaeuser, RA, Elke Pogge von Strandmann, PHD, Andreas Engert, MD, Peter J. Hudson, PHD, Barbara E. Power

Blood (2006) 108 (11): 4527.

https://doi.org/10.1182/blood.V108.11.4527.4527

Published: 2006

Journal Articles

Tumor Cell-Derived HLA-B-Associated Transkript 3 (BAT3) Is a Ligand for NKp30 and Activates NK Cells.

Elke Pogge von Strandmann, PhD, Venkateswara R. Simhadri, Bastian von Tresckow, MD, Stefanie Sasse, MD, Katrin S. Reiners, PhD, Hinrich P. Hansen, PhD, Achim Rothe, MD, Peter Borchmann, MD, Peter J. McKinnon, PhD, Michael Hallek, Andreas Engert

Blood (2006) 108 (11): 643.

https://doi.org/10.1182/blood.V108.11.643.643

Published: 2006

NARROW

Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

A Bispecific Protein Targeting the NKG2D Receptor on Natural Killer Cells: In Vitro and In Vivo activity of ULBP2-CEA

Selection of Human Anti-CD22 scFvs from an Acute Lymphocytic Leukemia Related scFv Library with Ribosome Display.

Tumor Cell-Derived HLA-B-Associated Transkript 3 (BAT3) Is a Ligand for NKp30 and Activates NK Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only